A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
National Institutes of Health Clinical Center (CC)
Aulos Bioscience, Inc.
BeOne Medicines
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
Children's Oncology Group
Essen Biotech
Essen Biotech
Sapience Therapeutics
University of California, Davis
Second Life Therapeutics
Inhibrx Biosciences, Inc
Regeneron Pharmaceuticals
DualityBio Inc.
University of Pittsburgh
University of Arizona
Hadassah Medical Organization
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Incyte Corporation
Cancer Research UK
NuCana plc
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Mural Oncology, Inc
Kymab Limited
Rabin Medical Center
Sarcoma Oncology Research Center, LLC
GI Innovation, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Vector Vitale LLC
GlaxoSmithKline
Pfizer
GeneMedicine Co., Ltd.
NextCure, Inc.
Novartis
HUYABIO International, LLC.
Rain Oncology Inc
Kineta Inc.
4D pharma plc
Western Sydney Local Health District
Nykode Therapeutics ASA